gen
5
Dott. Luigi Vicari on gennaio 5th, 2009
Abstral® is an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. The Abstral formulation delivers the analgesic power of fentanyl in a fast dissolving sublingual tablet. Abstral provides rapid relief of BTcP from 10 minutes1, provides predictable dosing2,3 and is convenient and easy to use.